Quebec and the capital, Quito, are facing a looming public health crisis as the country’s epidemic of Zika has subsided.
As the first shipment of PrEP, or pre-exposure prophylaxis, has been delivered, the World Health Organisation (WHO) announced that the drug is to be deployed in Paraguayan states that have been experiencing a wave of birth defects.
According to the announcement, the PrEP will be given to pregnant women who have not had their first pregnancy.
It is estimated that around 1.4 million people have been infected with the Zika virus in the country, where the disease has caused the death of more than 200,000 people.WHO spokesperson Joanne Fagot said that the country has seen an increase in cases, but that the number of deaths due to the disease is expected to be lower than in previous years.
“We have a very high incidence of birth defect in our country,” she said.
“But we expect that, with the additional support, we will see fewer deaths from the disease.”
This means that, for now, we have achieved the WHO’s target for the number and percentage of cases to be reduced.
“In recent months, the country had witnessed a dramatic rise in the number, but experts said that it was still too early to say whether it was the first of many to come.
The WHO also announced that it had launched a $15m fund for pregnant women affected by the Zika epidemic in the state of Quebac to help with their medical costs.
Fagot told reporters the government had started to distribute the funds and said the money would be used to help cover medical costs for pregnant mothers.
She also announced a new emergency operation centre for pregnant pregnant women to be established in the city of Santa Maria in the north of the country.”
In January, a team of WHO researchers conducted the first clinical trial of the drug in a small community of Paraguay.”
And we are looking forward to welcoming the women of Santa María and all the other centres in the region as well.”
In January, a team of WHO researchers conducted the first clinical trial of the drug in a small community of Paraguay.
The team tested three women who had been infected in their early 20s and had not yet been pregnant.
They found that the women who received the drug experienced fewer symptoms and less distress during their first trimester than the other women.
“These findings are an important step towards establishing a safe, effective and safe- for-work PrEP regimen for pregnant Paraguayans,” Fagsot said.